Matrix Capital Management — Full Portfolio
6 tracked investments · listed companies and verified rows first
Solve Therapeutics is a clinical-stage oncology biotech developing antibody-drug conjugates (ADCs) and radiopharmaceuticals for solid tumors, built around its CloakLink hydrophilic cleavable linker platform and an integrated diagnostic for patient selection.
BiotechDeep TechHealthtech
David Johnson(Chief Executive Officer)Clayton Knox(President)Katti Jessen(SVP, Translational Sciences)Yakov Kogan(Head of Operations)Brian Lannutti(Research & Development Leadership)Langdon Miller(Clinical Development Leadership)
Co-investorsDecheng CapitalYosemiteB Capital GroupB4 Capital
Palleon Pharma develops small molecule and biologic drugs targeting autoimmune and inflammatory diseases using proprietary glycoscience platforms.
BiotechDigital HealthMedical Devices
Jim Broderick(Co-Founder)Li Peng(Chief Scientific Officer)Stefani Wolff(Chief Development Officer)
Co-investorsPfizer VenturesPfizer Venture Investments
Workers' compensation management software company managing employee lifecycle from hire to retirement.
Overland Park, US
Matthew Condon(Executive Officer, Director)inJeff Hogland(Executive Officer, Director)Paul Morris(Executive Officer, Director)in
BoardRobert K Green(Director)Matthew Ferguson(Director)
Co-investorsKCRise FundNewRoad Capital Partners, LLC
Santa Clara-based provider of advanced threat protection software for detecting next-generation malware.
Santa Clara, US
Manoj Leelanivas(Executive Officer, Director)
Co-investorsClear VenturesSapphire VenturesZouk CapitalFoundation CapitalMatrixTrinity Ventures
BiotechSouth San Francisco, US
Aaron Tynes Hammack(Executive Officer, Director)Nicholas Conley(Executive Officer, Director)
BoardPing-Chuan Tsai(Director)
Co-investorsAlexandriaSv Tech Ventures, Inc.Viking Global Investors
Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Travis Wager(Co-founder, President and CSO)inHualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)inSimon Xi(Co-founder and CEO)inJackie Walling(CMO)Debasish Roychowdhury(Director)
Co-investorsDelos CapitalVivo CapitalAMR Action FundBoehringer Ingelheim Venture FundKorea Investment PartnersLilly Asia Ventures+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.